FIELD: pharmaceuticals.SUBSTANCE: invention relates to a composition for use in treating glioblastoma, wherein said composition comprises: (a) an effective amount of an antibody, an antibody fragment or diapers, which has B7-H3 specificity, and (b) an effective amount of an antibody or an antibody fragment which has specificity for VEGF or VEGFR. Invention also relates to use of an antibody, an antibody fragment or diapers, which has B7-H3 specificity, in combination with an antibody or antibody fragment which has specificity for VEGF or VEGFR, for treating glioblastoma, wherein the use provides: a) administering an effective amount of said antibody, antibody fragment or diapers, having B7-H3 specificity, and an effective amount of said antibody or antibody fragment having VEGF or VEGFR specificity simultaneously； or b) administering an effective amount of one of said antibody, antibody fragment or diapers, which has B7-H3 specificity, and an effective amount of said antibody or antibody fragment, which has specificity for VEGF or VEGFR, and then introduction of the other of said antibody, antibody fragment or diapers, which has B7-H3 specificity, or said antibody or antibody fragment, which has VEGF or VEGFR specificity, within 10 half-lives after administration of the first of said antibody, antibody fragment or diapers, which has specificity for B7-H3, or said antibody or antibody fragment, which has specificity with respect to VEGF or VEGFR.EFFECT: disclosed composition has improved efficacy against glioblastoma.9 cl, 2 ex, 9 dwg, 3 tblИзобретение относится к композиция для применения в лечении глиобластомы, где указанная композиция содержит: (a) эффективное количество антитела, фрагмента антитела или диатела, которое обладает специфичностью в отношении В7-Н3, и (b) эффективное количество антитела или фрагмента антитела, которое обладает специфичностью в отношении VEGF или VEGFR. Также изобретение относится к применению антитела, фрагмента антитела или диатела,
